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Introduction
We conducted an annually bloodstream infection (BSI)
survey into hospitals overlapping the Centre France region
(2.6 million). Since 2005, the incidence of BSIs associated
with ESBL-producing E. coli (ESBLEc) increased.
Objectives
To improve the understanding of the pathway and the
determination of the risk factors of ESBLEc-BSIs.
Methods
For each BSI, were reported patient age, sex, recent hos-
pitalization, living in nursing home, recent antibiotherapy,
urinary catheterization, BSI source, death within 7days of
diagnosis.
BSI isolates were studied: antimicrobial susceptibility,
determination of molecular mechanism associated with
ESBL-production, genetic diversity of ESBLEc (MLST).
Results
During the survey (474,953 PDs), 443 E. coli BSI were
identified, including 31 ESBLEc (7.0%; 30/31 CTX-M).
Incidence of community acquired(CA)- and healthcare
associated(HCA)-BSI were 0.47/100,000 and 0.040/1,000
PDs, respectively.
Major findings
For ESBLEc-CA-BSIs, male/female ratio was 1.4, median
age 80, urinary BSI source in 50% of cases, recent anti-
biotherapy in 33 %. Most ESBLEc were resistant to
fluoroquinolones (67%), SXT/TMP (67%). High genetic
diversity (8 STs including 4 ST131).
For ESBLEc-HCA-BSI, male/female ratio was 0.9,
median age 75, urinary BSI source in 63% of cases
(recent catheterization in 1/2), recent antibiotherapy in
58%. Most ESBLEC were resistant to fluoroquinolones
(79%), SXT/TMP (63%). Low genetic diversity (9 STs
including 7 ST131).
Among BSI, ESBLEc-BSI were associated with health-
care (p=0.004), long-stay unit (p=0.018), recent anti-
biotherapy (p=0.002). ESBLEc were associated with
resistance to fluoroquinolones, SXT/TMP and genta./
tobramycine (p<0.001).
Among ESBLEc-BSI, clinical determinants and BSI
characteristics similar whatever the clonal group excepted
for ST131 associated with long-stay unit (p=0.042).
Among ST131-BSI, clinical determinants and BSI
characteristics similar for ESBLEc and non ESBLEc
excepted median age higher in ESBLEc (80/67).
Conclusion
Recent antibiotherapy (and easy spread into long-stay units
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